Aldesleukin Recruiting Phase 3 Trials for Metastatic Melanoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02278887Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma